Consolidated Balance Sheets - USD ($) $ in Millions		Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents		$ 2,058	$ 2,165
Accounts receivables, net of allowance for credit losses of $95 million and $90 million as of June 30, 2022 and December 31, 2021		4,471	4,529
Inventories		4,049	3,818
Prepaid expenses		1,052	1,075
Other current assets		518	965
Assets held for sale		16	19
Total current assets		12,164	12,573
Deferred income taxes		1,595	596
Other non-current assets		454	515
Property, plant and equipment, net		5,740	5,982
Operating lease right-of-use assets		441	495
Identifiable intangible assets, net		6,700	7,466
Goodwill	[1]	18,837	20,040
Total assets		45,932	47,666
Current liabilities:
Short-term debt		1,719	1,426
Sales reserves and allowances		3,880	4,241
Accounts payables		1,901	1,686
Employee-related obligations		467	563
Accrued expenses		2,112	2,208
Other current liabilities		916	903
Total current liabilities		10,996	11,027
Long-term liabilities:
Deferred income taxes		532	784
Other taxes and long-term liabilities		3,842	2,578
Senior notes and loans		20,363	21,617
Operating lease liabilities		371	416
Total long-term liabilities		25,107	25,395
Commitments and contingencies, see note 10
Total liabilities		36,103	36,422
Teva shareholders' equity:
Ordinary shares of NIS 0.10 par value per share; June 30, 2022 and December 31, 2021: authorized 2,495 million shares; issued 1,216 million shares and 1,209 million shares, respectively.		57	57
Additional paid-in capital		27,625	27,561
Accumulated deficit		(11,716)	(10,529)
Accumulated other comprehensive loss		(2,801)	(2,683)
Treasury shares as of June 30, 2022 and December 31, 2021: 106 million ordinary shares		(4,128)	(4,128)
Stockholders' equity attributable to Teva shareholders		9,037	10,278
Non-controlling interests		791	966
Total equity		9,828	11,244
Total liabilities and equity		$ 45,932	$ 47,666

[1] Accumulated goodwill impairment as of June 30, 2022 and December 31, 2021 was approximately $26.3 billion and $25.6 billion, respectively.